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PATTERNS IN PRESCRIPTIONS OF ANTISYPCHOTICS FOR PATIENTS 
WITH MOOD DISORDERS AND THEIR OUTCOMES
Ramos PG
University of Louisville, Louisville, KY, USA
OBJECTIVES: To determine patterns in the prescriptions of antipsychotics in patients 
with mood disorders. To investigate adverse effects of antipsychotics in patients with 
mood disorders and their relationship to other prescription drugs. METHODS: The 
MarketScan database, for year 2000, containing information on outpatient doctor 
visits and consumption of prescription drugs on millions of Americans with health 
care coverage was used. Patients with at least a mood disorder were identiﬁed by ICD9 
codes. Their prescription drug record for this year was also identiﬁed. This was popu-
lated with drugs names by NDC codes tables from the FDA website. Antipsychotic 
drug use was categorized as ﬁrst generation or second generation and logistic regres-
sion was used to determine odds ration controlling on demographics. Furthermore, 
patients were classiﬁed as having a metabolic disorder, such as hyperglycemia or 
diabetes, and odds ratios were computed controlling for the generation of the anti-
psychotic. The data were also analyzed using data mining techniques such as cluster 
analysis and link analysis. RESULTS: Antipsychotics were highly used in the treatment 
of mood disorders. Second generation antipsychotics were prescribed almost two times 
more often than ﬁrst generation antipsychotics. The odds of having a metabolic dis-
order are almost 50% higher for patients using second generation antipsychotics than 
for patients using ﬁrst generation antipsychotics. Cluster analysis shows that metabolic 
disorders and other chronic diseases are rather common among patients with mood 
disorders. Link analysis shows that the use of second generation antipsychotics is 
strongly connected to the use of antidepressants. CONCLUSIONS: These ﬁndings 
suggest that people taking second generation antipsychotics should be closely monitor 
for the development of metabolic disorders. More efforts should be made to investigate 
the association between chronic diseases and mood disorders.
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OBJECTIVES: This analysis groups opioid users into misusers and non-misusers and 
characterizes them by potential risk factors that may help medical decision-makers 
identify and differentiate legitimate opioid users from misusers. METHODS: Patients 
with at least one opioid claim were identiﬁed in the commercial and Medicare Mar-
ketScan claims databases from January 1, 2000—December 31, 2008. All subjects had 
continuous eligibility from 6 months before the ﬁrst opioid claim to 24 months after. 
Subjects with at least one claim with a diagnosis of opioid abuse or dependence (ICD-9 
304.0x or 305.5x) were classiﬁed as misusers. Misusers were compared to other opioid 
users on demographics, comorbidities, pharmacy use, and medical service utilization. 
RESULTS: Of 2,841,793 opioid users who met all inclusion criteria, 2913 were 
diagnosed misusers. Mean age for misusers and non-misusers was 38 and 48 years 
respectively (p < 0.0001); misusers were 60% male versus 44% for non-misusers (p 
< 0.0001). Misusers used more opioids in 2 years than non-misusers: 273 days supply 
versus 33 days (p < 0.0001); 2.4 different short-acting opioids (SAO) versus 1.4 (p < 
0.0001); 1.4 different long-acting opioids (LAO) versus 1.1 (p < 0.0001). Misusers 
used more pharmacies than non-misusers: 3.3 different pharmacies versus 1.4 (p < 
0.0001). Misusers used more medical services (PMPY) than non-misusers: 10.3 physi-
cian visits versus 6.5 (p < 0.0001); 9.0 OP mental health visits versus 0.7 (p < 0.0001); 
0.8 IP admissions versus 0.1 (p < 0.0001). 54% of misusers had comorbid substance 
abuse versus 1% of non-misusers (p < 0.0001). Misusers used key concomitant drugs 
more than non-misusers: 22.7% gabapentin use versus 4.5% (p < 0.0001); 8.1% 
buspirone hydrochloride use versus 1.1% (p < 0.0001); 52.6% benzodiazepine use 
versus 19.5% (p < 0.0001); 40.4% muscle relaxant use versus 16.5% (p < 0.0001); 
44.7% SSRI use versus 14.6% (p < 0.0001). CONCLUSIONS: Among opioid 
users, diagnosed misusers likely do not represent all misusers, but they show clear 
differences from undiagnosed misusers in terms of comorbid conditions and health 
care service use.
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DEMOGRAPHIC RISK FACTORS AFFECTING BENZODIAZEPINE-
RELATED EMERGENCY ROOM VISITS IN KANSAS CITY, MO FROM 2001 
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OBJECTIVES: Misuse of benzodiazepine is associated with negative health outcomes 
at both individual and societal level. The study objective was to identify demographic 
risk factors associated with benzodiazepine-related emergency room visits. METHODS: 
We conducted the retrospective study using the Missouri Hospital Discharge Data for 
Kansas City, MO from 2001 to 2007. The data included patients’ demographic 
variables such as age, gender, ethnicity, health insurance status, and annual income. 
Patients with benzodiazepine-related emergency room visits were identiﬁed by ICD-9 
codes, and the frequencies of patient visits were calculated according to each of the 
demographic variables. A multiple logistic regression analysis was conducted, where 
the outcome variable was a benzodiazepine-related emergency room visit (yes/no), and 
the independent variables were the demographic variables. RESULTS: Of the 
1,317,566 emergency room visits over the seven year period, 562 were identiﬁed to 
be benzodiazepine-related. Fifty-one percent of the visits were by patients aged 25 to 
44, of whom 56% were female, 77% were white, 74% had health insurance, and 
44% had an annual income of $40,000 to $59,999. In the logistic regression, white 
patients were 73% more likely than black patients to have benzodiazepine-caused 
emergency room visits (p < 0.01), with an odds ratio (OR, 95%CI) of 5.63 (4.33–
7.30). Compared with those aged 0–19 years, the odds ratio for patients aged 30–39 
to have benzodiazepine-related emergency room visits was 2.73 (2.09–3.57), and the 
odds ratio for patients aged 40–49 was 2.84 (2.17–3.71). CONCLUSIONS: White 
patients aged 30–49 were at higher risk to have a benzodiazepine-related emergency 
room visit. Health interventions such as medication management services may reduce 
benzodiazepine-related emergency room visits for these patients.
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OBJECTIVES: Studies concerning metabolic effects associated with second generation 
antipsychotics (SGAs) fail to control for psychiatric comorbidities or medications 
known to affect weight. We analyzed a large administrative claims database to deter-
mine the associations of psychiatric comorbidity and polypharmacy and hospitaliza-
tion and expenditures among SGA users with metabolic syndrome (MetS). METHODS: 
Using descriptive and logistic regression analyses, we examined the effects of psychi-
atric comorbidity and polypharmacy on the association between SGAs (aripiprazole, 
ziprasidone, risperidone, quetiapine, and olanzapine) and hospitalization and expen-
ditures among antipsychotic users with MetS. Psychiatric comorbidities included 
schizophrenia, bipolar, depression, and other psychiatric disorders. Psychiatric poly-
pharmacy was concomitant use of antipsychotics with psychiatric drugs with meta-
bolic effects (selective serotonin reuptake inhibitors [SSRI], tricyclic antidepressants 
[TCA], other antidepressants, and mood stabilizers). We also controlled for sociode-
mographics and insurance. Outcomes of interest included all-cause hospitalization and 
expenditures, disaggregated to non-psychiatric and psychiatric-related events. 
RESULTS: SGA users with MetS were more likely to have hospitalization than 
non-SGA users with MetS (OR = 1.29; P < 0.05); however, the association became 
non-signiﬁcant upon controlling for psychiatric comorbidity and polypharmacy. 
Instead, having schizophrenia, bipolar, depression, or other psychiatric disorders 
signiﬁcantly increased the odds of hospitalization (ORs = 2.56, 1.44, 1.73, 2.06, 
respectively; all p < 0.0001), as did concomitant use of SSRIs or TCAs (ORs = 1.35 
and 1.36, respectively; both p < 0.01). Among MetS patients, total medical expenditure 
was higher in SGA users than non-SGA users (median $15,077 vs. $7,776, respec-
tively; p < 0.0001). Controlling for psychiatric comorbidities and polypharmacy in 
antipsychotic users with MetS, SGA use increased total expenditures by 16.6 % (p < 
0.0001). Psychiatric comorbidity and polypharmacy also signiﬁcantly contributed to 
total expenditures by 13–30% (p < 0.001). CONCLUSIONS: Among patients with 
MetS, psychiatric comorbidity and polypharmacy are associated with higher risk of 
hospitalization and expenditures in SGA users than non-SGA users. Findings suggest 
clinicians should consider patients’ psychiatric comorbidity and polypharmacy 
burdens when prescribing SGAs.
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NURSING HOME USE OF ATYPICAL ANTIPSYCHOTICS FOR 
BEHAVIORAL AND PSYCHOLOGICAL PROBLEMS OF ELDERLY WITH 
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OBJECTIVES: The key objective of this study was to review evidence regarding off-
label use of atypical antipsychotics for treating behavioral problems in patients with 
Dementia of Alzheimer’s type. A secondary objective was to examine patterns of 
atypical antipsychotic drug use in this population with respect to the extent and type 
of neurological and mental health co morbidities. METHODS: National Nursing 
Home Survey (NNHS, 2004), a nationally representative survey of US nursing home 
residents, was utilized to identify residents with senile dementia of the Alzheimer type 
(SDAT). Variables that represented attention to dementia care and special services for 
behavioral problems were analyzed to understand treatment patterns and associated 
medication use. Relationships between atypical antipsychotic drug use and the type 
and extent of neurological and mental health co morbidities were discerned using 
appropriate bivariate and multivariate statistics. RESULTS: The un-weighted resident 
sample yielded 1958 (14.5%) cases of SDAT, with more women (77.2%) than men. 
More than half of the residents diagnosed with the condition belonged to the age 
group 70 years or older. While 166 (8.5%) residents participated in a special program 
for dementia, about 238 (12.15%) of the residents received special services for behav-
ioral problems. 618 (31%) residents were prescribed at least one of the top three 
atypical anti-psychotic medications. Prevalence of neurological and mental health co 
morbidities varied from 37% (Depression), 7.8% (Psychosis), 3.9% (agitation) to 
1.8% (Schizophrenia). CONCLUSIONS: Prevalence of SDAT increases with age. The 
use of atypical antipsychotics is high in this segment of the nursing home population 
and a substantial portion of prescribing maybe off-label, especially when used for the 
treatment of behavioral problems. Existence of co morbidities may be a contributing 
factor to the increased prescribing of atypicals in nursing homes.
